BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · IEX Real-Time Price · USD
154.91
-1.62 (-1.03%)
Apr 30, 2024, 10:35 AM EDT - Market open
BeiGene Revenue
In the year 2023, BeiGene had annual revenue of $2.46B with 73.65% growth. Revenue in the quarter ending December 31, 2023 was $634.41M with 66.91% year-over-year growth.
Revenue (ttm)
$2.46B
Revenue Growth
+73.65%
P/S Ratio
6.74
Revenue / Employee
$231,960
Employees
10,600
Market Cap
16.55B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
Dec 31, 2013 | 11.15M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 144.60B |
Teva Pharmaceutical | 15.85B |
Viatris | 15.43B |
Laboratory Corporation of America Holdings | 12.16B |
Quest Diagnostics | 9.29B |
Hologic | 3.97B |
The Cooper Companies | 3.67B |
BioMarin Pharmaceutical | 2.47B |
BGNE News
- 4 days ago - BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report - Business Wire
- 5 days ago - Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting - Business Wire
- 7 days ago - BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - Business Wire
- 6 weeks ago - US FDA approves BeiGene's esophageal cancer therapy - Reuters
- 6 weeks ago - First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation - Business Wire
- 7 weeks ago - BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
- 7 weeks ago - US FDA approves expanded use of BeiGene's blood cancer drug - Reuters